Argenx Se (ARGX) Long-Term Investments (2020 - 2026)
Argenx Se's (ARGX) quarterly Long-Term Investments came in at $3.4 million in Q4 2025, down 63.55% YoY from $9.3 million in Q4 2024, and down 99.97% on a QoQ basis from $10.7 billion in Q2 2025.
Analysis
Argenx Se (ARGX) Long-Term Investments (2020 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Long-Term Investments data on file, last reported at $3.4 million in Q4 2025.
- Quarterly Long-Term Investments fell 63.55% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (down 63.55% YoY) and the FY2025 annual result came in at -$6.5 million, down 170.13% from the prior year.
- Long-Term Investments fell to $3.4 million in Q4 2025, from $10.7 billion in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $10.7 billion in Q2 2025 to a low of -$370.3 million in Q2 2021.
- A 5-year average of $1.0 billion and a median of $7.9 million in 2024 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2021 — Long-Term Investments slumped 223.7% — and 2025, when it jumped 161757.86%.
- Tracing ARGX's Long-Term Investments over 5 years: stood at $76.7 million in 2021, then slumped by 98.27% to $1.3 million in 2022, then jumped by 649.21% to $9.9 million in 2023, then slipped by 6.5% to $9.3 million in 2024, then tumbled by 63.55% to $3.4 million in 2025.
- The last three Long-Term Investments figures came in at $3.4 million (Q4 2025), $10.7 billion (Q2 2025), and $9.3 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 345.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.00 Mn |
| Dec 31, 2025 | 3.38 Bn |
| Jun 30, 2025 | 10.68 Bn |
| Dec 31, 2024 | 9.27 Bn |
| Jun 30, 2024 | 6.60 Mn |
| Dec 31, 2023 | 9.91 Mn |
| Jun 30, 2023 | 12.44 Mn |
| Dec 31, 2022 | 1.32 Bn |
| Jun 30, 2021 | 100.56 Mn |
| Dec 31, 2020 | 6.31 Mn |